**Actieve studies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Title | Phase | Tumortype | Line of Therapy | Study Information | Register |
| First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma | I/II | MPM | 1L | * Epitheloid mesothelioma * Q3W: Pemetrexed + Cisplatinum  + DC vaccination * Ongoing DC vaccination Q4W | NCT02649829 |
| A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671) | III | NSCLC  IIB or IIIA | Neoadjuvant/  Adjuvant | * Neoadjuvant Q3W: Pembrolizumab/Placebo + Gemcitabine/Pemetrexed + Cisplatinum * Adjuvant Q3W: Pembrolizumab/Placebo | [NCT03425643](https://clinicaltrials.gov/show/NCT03425643) |
| A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with NSCLC previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2) | III | NSCLC IIIB or metastatic | 2L/3L | * Q3W: Canakinumab/Placebo + Docetaxel | [NCT03626545](https://clinicaltrials.gov/show/NCT03626545) |
| ALK, ROS1 and MET testing in cell-free RNA and DNA for improved precision oncology guided management of non-small cell lung cancer patients | NA | NSCLC ROS, ALK and MET mutations | NA | The overall goal of the study is to assess the analytical performance to identify relevant mutations in ALK, ROS1 and MET in plasma from NSCLC patient. Doing so, we want to provide a rationale for a cost-effective testing procedure for future Belgian NSCLC patients for sensitive and straightforward mutation testing in easily accessible blood samples. | / |